Literature DB >> 9621042

Role of the SH3-ligand domain of simian immunodeficiency virus Nef in interaction with Nef-associated kinase and simian AIDS in rhesus macaques.

I H Khan1, E T Sawai, E Antonio, C J Weber, C P Mandell, P Montbriand, P A Luciw.   

Abstract

The nef gene of the human and simian immunodeficiency viruses (HIV and SIV) is dispensable for viral replication in T-cell lines; however, it is essential for high virus loads and progression to simian AIDS (SAIDS) in SIV-infected adult rhesus macaques. Nef proteins from HIV type 1 (HIV-1), HIV-2, and SIV contain a proline-Xaa-Xaa-proline (PxxP) motif. The region of Nef with this motif is similar to the Src homology region 3 (SH3) ligand domain found in many cell signaling proteins. In virus-infected lymphoid cells, Nef interacts with a cellular serine/threonine kinase, designated Nef-associated kinase (NAK). In this study, analysis of viral clones containing point mutations in the nef gene of the pathogenic clone SIVmac239 revealed that several strictly conserved residues in the PxxP region were essential for Nef-NAK interaction. The results of this analysis of Nef mutations in in vitro kinase assays indicated that the PxxP region in SIV Nef was strikingly similar to the consensus sequence for SH3 ligand domains possessing the minus orientation. To test the significance of the PxxP motif of Nef for viral pathogenesis, each proline was mutated to an alanine to produce the viral clone SIVmac239-P104A/P107A. This clone, expressing Nef that does not associate with NAK, was inoculated into seven juvenile rhesus macaques. In vitro kinase assays were performed on virus recovered from each animal; the ability of Nef to associate with NAK was restored in five of these animals as early as 8 weeks after infection. Analysis of nef genes from these viruses revealed patterns of genotypic reversion in the mutated PxxP motif. These revertant genotypes, which included a second-site suppressor mutation, restored the ability of Nef to interact with NAK. Additionally, the proportion of revertant viruses increased progressively during the course of infection in these animals, and two of these animals developed fatal SAIDS. Taken together, these results demonstrated that in vivo selection for the ability of SIV Nef to associate with NAK was correlated with the induction of SAIDS. Accordingly, these studies implicate a role for the conserved SH3 ligand domain for Nef function in virally induced immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621042      PMCID: PMC110384     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques.

Authors:  S M Lang; A J Iafrate; C Stahl-Hennig; E M Kuhn; T Nisslein; F J Kaup; M Haupt; G Hunsmann; J Skowronski; F Kirchhoff
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

Review 2.  Murine and simian retrovirus models: the threshold hypothesis.

Authors:  R M Ruprecht; T W Baba; R Rasmussen; Y Hu; P L Sharma
Journal:  AIDS       Date:  1996       Impact factor: 4.177

3.  HIV-1 Nef association with cellular serine kinase correlates with enhanced virion infectivity and efficient proviral DNA synthesis.

Authors:  M Wiskerchen; C Cheng-Mayer
Journal:  Virology       Date:  1996-10-01       Impact factor: 3.616

4.  Activation of the T-cell receptor signaling pathway by Nef from an aggressive strain of simian immunodeficiency virus.

Authors:  W Luo; B M Peterlin
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection.

Authors:  R Mariani; F Kirchhoff; T C Greenough; J L Sullivan; R C Desrosiers; J Skowronski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 6.  The role of Nef in the replication cycle of the human and simian immunodeficiency viruses.

Authors:  B R Cullen
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

Review 7.  HIV-1 Nef and host cell protein kinases.

Authors:  K Saksela
Journal:  Front Biosci       Date:  1997-12-15

8.  Simian immunodeficiency virus/delta-induced immunodeficiency disease in rhesus monkeys: relation of antibody response and antigenemia.

Authors:  J Y Zhang; L N Martin; E A Watson; R C Montelaro; M West; L Epstein; M Murphey-Corb
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

9.  Identification and biologic characterization of an acutely lethal variant of simian immunodeficiency virus from sooty mangabeys (SIV/SMM).

Authors:  P N Fultz; H M McClure; D C Anderson; W M Switzer
Journal:  AIDS Res Hum Retroviruses       Date:  1989-08       Impact factor: 2.205

10.  The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.

Authors:  M D Miller; M T Warmerdam; I Gaston; W C Greene; M B Feinberg
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  31 in total

1.  Disrupting surfaces of nef required for downregulation of CD4 and for enhancement of virion infectivity attenuates simian immunodeficiency virus replication in vivo.

Authors:  A J Iafrate; S Carl; S Bronson; C Stahl-Hennig; T Swigut; J Skowronski; F Kirchhoff
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  The soluble ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry.

Authors:  Francesca Cocchi; Daniela Fusco; Laura Menotti; Tatiana Gianni; Roselyn J Eisenberg; Gary H Cohen; Gabriella Campadelli-Fiume
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

3.  CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

4.  Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef.

Authors:  E T Sawai; M S Hamza; M Ye; K E Shaw; P A Luciw
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Genetic and functional diversity of human immunodeficiency virus type 1 subtype B Nef primary isolates.

Authors:  J L Foster; R P Molina; T Luo; V K Arora; Y Huang; D D Ho; J V Garcia
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 6.  Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.

Authors:  Ryan P Staudt; John J Alvarado; Lori A Emert-Sedlak; Haibin Shi; Sherry T Shu; Thomas E Wales; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2020-08-29       Impact factor: 5.157

7.  A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

8.  Lentiviral Nef proteins utilize PAK2-mediated deregulation of cofilin as a general strategy to interfere with actin remodeling.

Authors:  Bettina Stolp; Libin Abraham; Jochen M Rudolph; Oliver T Fackler
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

9.  Meta-analysis to test the association of HIV-1 nef amino acid differences and deletions with disease progression.

Authors:  Ravindra Pushker; Jean-Marc Jacqué; Denis C Shields
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 Nef recruits the guanine exchange factor Vav1 via an unexpected interface into plasma membrane microdomains for association with p21-activated kinase 2 activity.

Authors:  Susanne Rauch; Kati Pulkkinen; Kalle Saksela; Oliver T Fackler
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.